Immediate adjuvant cisplatin-based combination chemotherapy after radical cystectomy in patients with transitional cell carcinoma of the bladder significantly increased progression-free survival, according to the final results of the EORTC 30994 trial.
A reduced estimated glomerular filtration rate (eGFR) was found to be associated with a significantly increased risk for renal and urothelial cancer, according to the results of a recently published study.
Neoadjuvant treatment with dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin was well tolerated and should be considered a reasonable option for patients with muscle-invasive urothelial cancer, according to a new study.
A noninvasive DNA methylation test using urine samples from patients with non–muscle-invasive bladder cancer can detect cancer recurrence. The test demonstrated both specificity and sensitivity in detecting recurrence.